WA-SPIE
17.12.2020 17:07:15 CET | Business Wire | Press release
SPIE Photonics West , which normally convenes in San Francisco, will be held as an interactive, virtual conference 6-11 March 2021. North America’s largest optics and photonics technology event – with its popular BiOS, LASE, and OPTO conferences – held by SPIE, the international society for optics and photonics , also includes two digital exhibitions and the industry-focused Quantum West. Registration for SPIE Photonics West will open 5 January.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005110/en/
In addition to SPIE Photonics West, the following SPIE 2021 conferences will also be held via the organization’s digital-forum platform: SPIE Advanced Lithography ; SPIE Medical Imaging ; SPIE AR/VR/MR ; and SPIE Smart Structures + Nondestructive Evaluation .
“The SPIE Digital Forum platform was developed to help people share results and make connections during the pandemic, and we’ve continued to fine-tune our virtual platform and digital offerings throughout this year,” says SPIE CEO Kent Rochford. “We’ll be implementing the latest improvements during Photonics West and are excited to release them to our attendees, presenters, and exhibitors. These forums, as always, ensure the professional discussion, innovation sharing, and networking opportunities that the SPIE community values and relies on to advance its research, product development, and engineering collaborations.”
"It's been a challenging year for our entire community, and I know that I am not alone in my desire to meet in person to exchange ideas, research, technological advances, and new products," says 2020 SPIE President John Greivenkamp. "We are hopeful of being able to gather in person later in 2021. In the meantime, I invite you to join us online at one or more of these dynamic conferences and look forward to seeing you there."
Each year, SPIE Photonics West showcases the latest in applications, technologies, and discoveries in optics and photonics, with three major conference tracks: BiOS, highlighting new research in biophotonics, biomedical optics, and applications of medical imaging; LASE, with its focus on the laser industry and applications; and OPTO, showcasing optoelectronics, photonic materials, and related devices. In addition, the symposium is introducing a new conference, highlighting photonics research and technologies addressing COVID-19 . Photonics West will also feature a Digital Marketplace with product demos showcasing the latest in optics and photonics technologies and opportunities to connect with the industry’s leading suppliers and companies.
The SPIE Digital Forums will offer a convenient, high-quality, and timely way for researchers, engineers, and government and industry leaders in the photonics community to share emerging research, new results, and technological advances with their peers. The SPIE online format makes presentations and discussion accessible during the Forum in whatever time zone is convenient for the participant and in any order. In addition, the Digital Forums will include networking opportunities, live plenary sessions, and special events. All conference presentations and manuscripts will be accessible after the conference via the SPIE Digital Library . Registration and pricing information is available on each event webpage.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5.8 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005110/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom